• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Tenaya Therapeutics Inc. (Amendment)

    2/14/24 4:19:04 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TNYA alert in real time by email
    SC 13D/A 1 d726884dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    TENAYA THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    87990A106

    (CUSIP Number)

    James Evangelista

    The Column Group

    1 Letterman Drive,

    Building D, Suite DM-900

    San Francisco, CA 94129

    (415) 865-2050

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 12, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Securities Exchange Act”) or otherwise subject to the liabilities of that section of the Securities Exchange Act but shall be subject to all other provisions of the Securities Exchange Act (however, see the Notes).

     

     

     


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    The Column Group III, LP

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    WC

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    4,414,720 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    4,414,720 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    4,414,720 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    5.7% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    PN

     

    (1)

    All such shares are held of record by TCG III LP (as defined in Item 2(a) of the Original Schedule 13D as defined below). TCG III GP LP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. All shares are held of record by TCG LP (as defined in Item 2(a) of the Original Schedule 13D).

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, after the conclusion of the February Follow-on Offering (as defined in Item 3 below), as reported by the Issuer in its Prospectus Supplement filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b)(5) on February 8, 2024 (the “Prospectus Supplement”).


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    The Column Group III-A, LP

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    WC

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    4,985,570 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    4,985,570 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    4,985,570 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    5.7% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    PN

     

    (1)

    All such shares are held of record by TCG III-A LP (as defined in Item 2(a) of the Original Schedule 13D). TCG III GP LP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, as reported by the Issuer in the Prospectus Supplement.


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    The Column Group III GP, LP

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    9,400,290 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    9,400,290 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    9,400,290 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    12.2% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    PN

     

    (1)

    Consists of (i) 4,414,720 shares held of record by TCG III LP and (ii) 4,985,570 shares held of record by TCG III-A LP. TCG III GP LP is the general partner of each of TCG III LP and TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing partners of TCG III GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, as reported by the Issuer in the Prospectus Supplement.


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    The Column Group Opportunity III, LP

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    WC

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    13,599,275 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    13,599,275 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    13,599,275 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    17.7% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    PN

     

    (1)

    All such shares are held of record by TCG Opportunity III LP (as defined in Item 2(a) of the Original Schedule 13D). TCG Opportunity III GP LP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, as reported by the Issuer in the Prospectus Supplement.


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    The Column Group Opportunity III GP, LP

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    13,599,275 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    13,599,275 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    13,599,275 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    17.7% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    PN

     

    (1)

    All such shares are held of record by TCG Opportunity III LP. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, as reported by the Issuer in the Prospectus Supplement.


    CUSIP No. 87990A106

     

    1.   

    Name of Reporting Person

     

    TCG Opportunity III GP, LLC

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☒

     

    3.   

    SEC Use Only:

     

    4.   

    Source of Funds (See Instructions):

     

    AF

    5.   

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

     

    ☐

    6.   

    Citizenship or Place of Organization:

     

    Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       7.   

    Sole Voting Power:

     

    0

       8.   

    Shared Voting Power:

     

    13,599,275 (1)

       9.   

    Sole Dispositive Power:

     

    0

       10.   

    Shared Dispositive Power:

     

    13,599,275 (1)

    11.   

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    13,599,275 (1)

    12.   

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

     

    ☐

    13.   

    Percent of Class Represented by Amount in Row (11):

     

    17.7% (2)

    14.   

    Type of Reporting Person (See Instructions):

     

    OO

     

    (1)

    All such shares are held of record by TCG Opportunity III LP. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson, David Goeddel, a member of the Issuer’s board of directors, and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 76,999,909 shares of Common Stock outstanding as of February 12, 2024, as reported by the Issuer in the Prospectus Supplement.


    SCHEDULE 13D

    Explanatory Note:

    This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Common Stock, par value $0.0001 per share (“Common Stock”), of Tenaya Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 2 (this “Amendment”) supplements and amends the Schedule 13D relating to the Common Stock of the Issuer that was filed with the Commission on December 1, 2022, as amended by Amendment No. 1 filed with the Commission on February 21, 2023 (collectively, the “Original Schedule 13D”), previously reported on a Schedule 13G filed with the Commission on February 11, 2022 (the “Schedule 13G”). The Schedule 13G was filed pursuant to Rule 13d-1(d) of the Securities Exchange Act. This Amendment is being filed to report the purchases by the Reporting Persons of shares of Common Stock as set forth in Item 3 of this Statement. Only those items that are reported are hereby amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.

    Item 3. Source and Amount of Funds or Other Consideration

    Item 3 of the Original Schedule 13D is hereby amended by adding the following as the last paragraphs thereof:

    On March 10, 2023, TCG Opportunity III LP purchased 6,779 shares of Common Stock for a weighted-average purchase price of $2.5956 per share and an aggregate purchase price of $17,595.57.

    On February 12, 2024, TCG Opportunity III LP purchased 2,222,222 shares of Common Stock in the Issuer’s follow-on offering for a purchase price of $4.50 per share (the “February Follow-On Offering”) and an aggregate purchase price of $9,999,999.00.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Original Schedule 13D is hereby amended by adding the following language as the last paragraph thereof:

    In connection with the February Follow-on Offering, each of TCG III LP, TCG III-A LP and TCG Opportunity III LP entered into a lock-up agreement, pursuant to which each such party agreed, subject to certain exceptions, not to sell, transfer or otherwise convey certain of the Issuer’s securities held by TCG III LP, TCG III-A LP or TCG Opportunity III LP for 60 days following the date of the final prospectus for the February Follow-on Offering. The terms and provisions of such lock-up agreement are described more fully in the prospectus supplement for the February Follow-on Offering, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 5 to this Statement and is incorporated herein by reference.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 5:    Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (included as Exhibit A to the form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s Current Report on Form 8-K as filed with the Commission on February 8, 2024 (SEC File No. 001-40656) and incorporated herein by reference).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024.

     

    THE COLUMN GROUP III, LP       THE COLUMN GROUP III GP, LP
    By:    The Column Group III GP, LP         
    By:    /s/ James Evangelista, Attorney in Fact       By:    /s/ James Evangelista, Attorney in Fact
    Name:    James Evangelista       Name:    James Evangelista
    Title:    Attorney in Fact       Title:    Attorney in Fact
    THE COLUMN GROUP III-A, LP       THE COLUMN GROUP OPPORTUNITY III, LP
    By:    The Column Group III GP, LP       By:    The Column Group Opportunity III GP, LP
             By:    TCG Opportunity III GP, LLC
    By:    /s/ James Evangelista, Attorney in Fact       By:    /s/ James Evangelista, Attorney in Fact
    Name:    James Evangelista       Name:    James Evangelista
    Title:    Attorney in Fact       Title:    Attorney in Fact

    THE COLUMN GROUP OPPORTUNITY III

    GP, LP

          TCG OPPORTUNITY III GP, LLC
    By:    TCG Opportunity III GP, LLC         
    By:    /s/ James Evangelista, Attorney in Fact       By:    /s/ James Evangelista, Attorney in Fact
    Name:    James Evangelista       Name:    James Evangelista
    Title:    Attorney in Fact       Title:    Attorney in Fact
    Get the next $TNYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNYA

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    More analyst ratings

    $TNYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

      Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

      4/26/23 7:00:00 AM ET
      $NKTX
      $TNYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

      SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

      12/7/22 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Provides 2022 Business Updates

      Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic

      1/10/22 8:00:00 AM ET
      $EXEL
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:15:53 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Financials

    Live finance-specific insights

    See more
    • Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

      TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

      12/17/24 7:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

      SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

      12/16/24 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Stehman-Breen Catherine

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:54:13 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walsh Jeffrey T.

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:53:37 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Burroughs Amy L.

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:52:57 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    SEC Filings

    See more
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/30/25 4:32:02 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/15/25 9:32:51 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Tenaya Therapeutics Inc.

      SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/14/25 4:18:42 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Tenaya Therapeutics

      William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

      6/10/24 7:25:34 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

      11/30/23 7:50:26 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

      6/15/22 7:41:04 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 5:46:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 1:22:39 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 5:01:36 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $0.4373 per share, which is equal to the closing price of Tenaya's common stock on May 15, 2025. Each stock option has a ten-year term and vests as follows over a total of fou

      5/15/25 9:00:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya's core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and

      5/13/25 8:30:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies tha

      5/7/25 4:05:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care